Pomalidomide, > = 98% (HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Pomalidomide has been used:to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptidesfor apoptosis studies and intracellular calcium analysisas a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β;-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells

Biochem/physiol Actions

Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog.

Pomalidomide is an effective fetal hemoglobin (HbF) inducer that downregulates the key γ-globin repressors, SRY-box transcription factor 6 (SOX6), and BAF chromatin remodeling complex subunit (BCL11A).

Features and Benefits

This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle